One study on pancreatic cancer cells performed using the gemcitabine-resistant cell line, MIA PaCa-2, suggested modulation of hCNT1 expression by proteasomal inhibitors or selective miRNA antagonists [17]. This evidence concerns the gene SLC28A1 and familial pancreatic carcinoma.